Joseph K. Schachle

Executive

Opus Genetics, Inc.Ocuphire Pharma, Inc.

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 1 saleMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 1 saleAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€3,749

▼ Sales (3 ops.)

€50k

Latest filing published 27 Jul 2026 for Opus Genetics, Inc., €12k. Read the official filing

Filing timeline

BuySale

Joseph K. Schachle

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Joseph K. Schachle: trading record in brief

Joseph K. Schachle is a declared insider of Opus Genetics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 21 March 2024 to 23 July 2026, the count stands at 6 filings.

In open-market terms, that means 1 purchase worth €3,749 on one side and 3 sales worth €50k on the other. The net balance comes to €46k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants. In 2026 alone, the filings show no purchases and 3 sales.

The latest filing, published on 27 July 2026, reports an open-market sale of €12k in Opus Genetics, Inc. The last purchase on record was published on 25 March 2024, which is 937 days ago. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.